BioLineRx (BLRX) Q2 2026 earnings summary

Executive summary

• GLIX1 clinical program advanced with ongoing Phase I/IIa trial in glioblastoma, strong blood-brain barrier penetration, and promising safety profile; second cohort dosing underway, third cohort to start in September.

• New preclinical data show GLIX1's efficacy in temozolomide-resistant GBM and strong synergy with PARP inhibitors in HR-proficient ovarian cancer models; expansion of Phase IIa trial to include ovarian cancer planned.

• Motixafortide continues development in pancreatic cancer through a Phase IIb trial, with interim futility analysis expected in 2026.

• APHEXDA generated $1.6 million in sales for Ayrmid in Q2 2026, resulting in $0.3 million royalty revenue.

• Presentation acceptances at major oncology conferences (EANO, SNO, ESMO) for GLIX1 data and ongoing discussions with PARP inhibitor developers for collaborations.

Financial highlights

• Q2 2026 revenues were $0.3 million, flat year-over-year, mainly from APHEXDA royalties.

• Research and development expenses rose to $2.9 million, up 26.5% year-over-year, driven by GLIX1 project costs.

• General and administrative expenses increased to $0.9 million, mainly due to the absence of a prior period reversal of a doubtful account provision.

• Non-operating expenses decreased to $0.7 million from $1.9 million, primarily due to fair value adjustments of warrant liabilities.

• Net loss for Q2 2026 was $4.3 million, compared to $3.9 million in Q2 2025.

• Cash and equivalents stood at $13.1 million at quarter-end, with an additional $3.75 million raised or expected post-quarter.

Outlook and guidance

• Phase I data for GLIX1 expected in the first half of 2027; Phase IIa expansion to include additional cancer cohorts.

• Sufficient cash to fund operations into the first half of 2027.

• Entered a definitive agreement for a $3.75 million offering, expected to close by August 31, 2026.

• Anticipates interim/futility analysis for the CheMo4METPANC Phase IIb trial in 2026.